Foundry120 atlas

Bacteria in colitis associated cancer development

Download from source ↗

Dataset overview

Participants 115
Samples 265
Reuse readiness 5.6/10 evidence-backed score

Bacterial Oncotraits Rather than Spatial Organization Are Associated with Dysplasia in Ulcerative Colitis.

Abstract

<h4>Background and aims</h4>Colonic bacterial biofilms are frequently present in ulcerative colitis [UC] and may increase dysplasia risk through pathogens expressing oncotraits. This prospective cohort study aimed to determine [1] the association of oncotraits and longitudinal biofilm presence with dysplasia risk in UC, and [2] the relation of bacterial composition with biofilms and dysplasia risk.<h4>Methods</h4>Faeces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls. Oncotraits [FadA of Fusobacterium, BFT of Bacteroides fragilis, colibactin [ClbB] and Intimin [Eae] of Escherichia coli] were assessed in faecal DNA with multiplex quantitative polymerase chain reaction [qPCR]. Biopsies were screened for biofilms [n = 873] with 16S rRNA fluorescent in situ hybridiation. Shotgun metagenomic sequencing [n = 265], and ki67-immunohistochemistry were performed. Associations were determined with a mixed-effects regression model.<h4>Results</h4>Biofilms were highly prevalent in UC patients [90.8%] with a median persistence of 3 years (interquartile range [IQR] 2-5 years). Biofilm-positive biopsies showed increased epithelial hypertrophy [p = 0.025] and a reduced Shannon diversity independent of disease status [p = 0.015], but were not significantly associated with dysplasia in UC: adjusted odds ratio [aOR] 1.45, 95% confidence interval [CI] 0.63-3.40. In contrast, ClbB independently associated with dysplasia [aOR 7.16, 95% CI 1.75-29.28], and FadA and Fusobacteriales were associated with a decreased dysplasia risk in UC [aOR 0.23, 95% CI 0.06-0.83, p <0.01].<h4>Conclusions</h4>Biofilms are a hallmark of UC; however, because of their high prevalence are a poor biomarker for dysplasia. In contrast, colibactin presence and FadA absence independently associate with dysplasia in UC and might therefore be valuable biomarkers for future risk stratification and intervention strategies.

Study facts

Organism
Platform
Age group
Disease groups
Non-IBD controls, Ulcerative colitis
Anatomical sites

Data availability

Specific data assets have not been resolved from the source yet — see the source repository below for the full file listing.

Strengths & limitations for reuse

Strengths

  • Participant counts are documented
  • Sample counts are documented

Limitations

  • Not documented: raw reads are advertised
  • Not documented: feature/otu tables are advertised
  • Not documented: taxonomic tables are advertised
Extraction evidence & provenance

Each extracted field is shown with the source excerpt and location used to resolve it.

Assay

FieldValueEvidence
assay.sequencing_type shotgun_metagenomics from source
Shotgun metagenomic sequencing [n=265]

Section ENA study description, offset 3830

Cohort

FieldValueEvidence
cohort.disease_activity_metadata_available True
Endoscopic assessment of the severity of inflammation was performed for each biopsy location using the endoscopic Mayo score.

Section 2.3. Tissue and faecal sample collection, offset 8400

cohort.non_ibd_controls 35 from source
collected from 80 UC patients and 35 controls

Section ENA study description, offset 3550

cohort.study_design longitudinal inferred
We performed a prospective cohort study and employed an additional retrospective longitudinal arm

Section 2.1. Study design, offset 6100

cohort.total_participants 115 computed
Faeces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls.

Section ENA study description, offset 3500

cohort.treatment_exposure_documented True
68.8% used aminosalicylates and 17.5% were on biologic therapy.

Section 3.1.1. Baseline characteristics, offset 15100

cohort.ulcerative_colitis_participants 80 from source
collected from 80 UC patients and 35 controls

Section ENA study description, offset 3550

Data_Assets

FieldValueEvidence
data_assets.raw_reads False
Raw sequencing data with human reads will not be publicly available because of General Data Protection Regulation [GDPR].

Section Data availability, offset 41000

Specimens

FieldValueEvidence
specimens.body_site ascending and descending colon
From all patients, biopsies were taken from the ascending and descending colon

Section 2.3. Tissue and faecal sample collection, offset 8400

specimens.inflamed_status_available True
Endoscopic assessment of the severity of inflammation was performed for each biopsy location using the endoscopic Mayo score.

Section 2.3. Tissue and faecal sample collection, offset 8500

specimens.longitudinal_sampling True
additional retrospective longitudinal arm for in-depth biofilm characterisation

Section 2.1. Study design, offset 6100

specimens.number_of_samples 265 from source
Shotgun metagenomic sequencing [n=265] ... were performed.

Section ENA study description, offset 3850

specimens.sample_type mucosal_biopsy
Metagenomic shotgun analysis of left- and right-sided biopsies revealed that the bacterial composition in UC patients differed

Section 3.3.3. Bacterial composition in UC patients and biofilms, offset 26300